Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › CT-388 phase 2

CT-388 phase 2

CT-388 · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
CT-388
Population
obesity
Phase
2
Duration
48 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
CT-388 24 mgobesity48—−22.7 % vs −0.2 %
Δ −22.5 pp
————————verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (1)
  • CT-388 24 mg · weight_eff · Conclusion
    CT-388 demonstrated significant, dose-dependent WL of up to 22.7%

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: CT-388 phase 2. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/ct-388-phase-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.